Phase I Study to Assess the Tolerability and Efficacy of Selinexor (KPT-330) as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Patients With AML and High Risk MDS After Allogeneic Stem Cell Transplantation
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- MTD of selinexor, determined according to incidence of DLT as graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03
研究概览
简要总结
This phase I trial studies the side effects and best dose of selinexor when given after stem cell transplant in treating patients with acute myeloid leukemia that is at intermediate or high risk of spreading or coming back (intermediate- or high-risk), or myelodysplastic syndrome that is at high risk of spreading or coming back (high-risk). Selinexor works to stop cancer growth by blocking an enzyme, which may cause cancer cells to die and also kill cells that cause the cancer to grow, which commonly do not respond to regular chemotherapy.
详细描述
PRIMARY OBJECTIVES:
I. To determine the maximum tolerated dose (MTD) of selinexor in patients with hematologic malignancies, especially acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS), after allogeneic (allo)-stem cell transplant (SCT).
SECONDARY OBJECTIVES:
I. To evaluate the toxicities of selinexor as maintenance treatment after allo-SCT.
II. To determine the incidence of non-relapse mortality. III. To determine 2 years post SCT progression-free survival (PFS) and overall survival rates.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed, written informed consent in accordance with federal, local, and institutional guidelines
- •Patients underwent allo-SCT with intermediate risk and high risk AML and high risk MDS (defined by American Society for Blood and Marrow Transplantation [ASBMT] criteria), who are within 60 to 100 days after allo-SCT
- •There is no evidence of disease relapse at the time of screening, and minimal residual disease (MRD) is acceptable
- •Eastern Cooperative Oncology Group (ECOG) performance status of =< 2
- •Absolute neutrophil count (ANC) > 1000 uL
- •Platelets >= 20,000 without platelet transfusion
- •Creatinine clearance > 30 cc/min calculated using the Cockcroft and Gault (1976) formula or measured
- •Total bilirubin =< 2 mg/dl unless high indirect bilirubin is due to a congenital disorder
- •Transaminases (aspartate aminotransferase [AST] or alanine aminotransferase [ALT]) =< 2.0 x upper limit of normal (ULN)
- •Prothrombin time (PT) and partial thromboplastin time (PTT) =< 2 x ULN
- •Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests and other study procedures
- •It is important patients understand the need to use birth control while on this study; female patients of child-bearing potential must agree to use dual methods of contraception and have a negative serum pregnancy test at screening (< 3 days prior to first dose), male patients with partners of childbearing potential must agree to use effective contraception during the study period and a period of 3 months after the last dose of study drug; for both male and female patients, effective methods of contraception must be used throughout the study and for three months following the last dose
排除标准
- •Patients with acute GVHD grade II-IV
- •Treatment with any investigational agent within three weeks prior to first dose in this study
- •Major surgery within 2 weeks of first dose of study drug; patients must have recovered from the effects of any surgery performed greater than 2 weeks previously
- •Patient has a concurrent active malignancy under treatment
- •Unstable cardiovascular function:
- •Symptomatic ischemia, or
- •Uncontrolled clinically significant conduction abnormalities (i.e., ventricular tachycardia on antiarrhythmic agents are excluded; 1st degree atrioventricular (AV) block or asymptomatic left anterior fascicular block/right bundle branch block (LAFB/RBBB) will not be excluded), or
- •Congestive heart failure (CHF) NYHA class >= 3, or
- •Myocardial infarction (MI) within 3 months
- •Uncontrolled infection requiring parenteral antibiotics, antivirals, or antifungals within one week prior to first dose; infections controlled on concurrent anti-microbial agents are acceptable, and anti-microbial prophylaxis per institutional guidelines are acceptable
- •Known active hepatitis B virus (HBV) or C virus (HCV) infection; or known to be positive for HCV ribonucleic acid (RNA) or HBsAg (HBV surface antigen)
- •Known human immunodeficiency virus (HIV) infection
- •Any medical condition which, in the investigator's opinion, could compromise the patient's safety
- •Patients unable to swallow tablets or patients with malabsorption syndrome, or any other disease significantly affecting gastrointestinal function
研究组 & 干预措施
Treatment (selinexor)
Beginning on day 60-100 after allo-SCT without evidence of GVHD above grade 1 and disease relapse with stable hematopoietic recovery, patients receive selinexor PO on day 1 of each week or on days 1 and 3 of weeks 1-3. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
干预措施: Laboratory Biomarker Analysis (Other)
Treatment (selinexor)
Beginning on day 60-100 after allo-SCT without evidence of GVHD above grade 1 and disease relapse with stable hematopoietic recovery, patients receive selinexor PO on day 1 of each week or on days 1 and 3 of weeks 1-3. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
干预措施: Selinexor (Drug)
结局指标
主要结局
MTD of selinexor, determined according to incidence of DLT as graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03
时间窗: Up to 29 days
次要结局
- Incidence of acute GVHD(Up to 2 years)
- Lymphoid and myeloid chimerism post transplantation(Up to 2 years)
- PFS(From the date of allo-SCT to the date of disease relapse or death, assessed up to 2 years)
- Incidence of adverse events (AEs), graded according to NCI CTCAE version 4.03(Up to 2 years)
- Incidence of chronic GVHD(Up to 2 years)
- Incidence of non-relapse mortality(Up to 2 years)
- Overall survival (OS)(From the date of allo-SCT to the date of disease relapse or death, assessed up to 2 years)